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 Many cancers evade immune rejection by suppressing MHC-I antigen processing and 
presentation (AgPP). Such cancers do not respond to immune checkpoint inhibitor therapies (ICIT) such 
as PD-1/PD-L1 [PD-(L)1] blockade. Certain chemotherapeutic drugs augment tumor control by PD-(L)1 
inhibitors through potentiation of T cell priming but whether and how chemotherapy enhances MHC-I 
dependent cancer cell recognition by cytotoxic T cells (CTL) is not entirely clear. We now show that the 
lysine acetyl transferases p300/CBP control MHC-I AgPPM expression and neoantigen amounts in 
human cancers. Moreover, we found that two distinct DNA damaging drugs, the platinoid oxaliplatin and 
the topoisomerase inhibitor mitoxantrone, strongly upregulate MHC-I AgPP in a manner dependent on 
activation of NF- B, p300/CBP and other transcription factors, but independently of autocrine IFN  
signaling. Accordingly, NF- B and p300 ablations prevent chemotherapy-induced MHC-I AgPP and 
abrogate rejection of low MHC-I expressing tumors by re-invigorated CD8+ CTL. Drugs like oxaliplatin and 
mitoxantrone may be used to overcome resistance to PD-(L)1 inhibitors in tumors that had “epigenetically 





T cells recognize their targets via their T cell receptors (TCR), which in the case of CD8+ T cells bind to 
MHC-I:antigen complexes on the surface of target cells. Many cancer cells evade immune recognition 
and killing by downregulating MHC-I AgPPM. Here, we show how the histone acetyl transferases 
P300/CBP together with NF-κB epigenetically regulate expression of MHC-I molecules, 
immunoproteasome subunits and peptide transporter to enable proper MHC-I antigen presentation. 
Notably, this pathway is frequently disrupted in human cancers. We now show that certain 
chemotherapeutics can augment MHC-I antigen presentation via NF-κB and p300/CBP activation thereby 






 Immune checkpoint inhibitor therapy (ICIT) had transformed cancer treatment (1–4), but even in 
ICIT-responsive metastatic melanoma and non-small cell lung cancer (NSCLC), response rates rarely 
exceed 40% (5). Other malignances, including prostate cancer (PCa) and pancreatic ductal 
adenocarcinoma (PDAC), are ICIT refractory (6–9). For a given neoplasm to respond to immune 
checkpoint inhibition, in particular PD-(L)1 blockade, it needs to be populated by CTL that recognize 
tumor antigens (4). However, even CTL populated tumors can evade immune elimination either through 
activation of immunosuppressive mechanisms that induce CD8+ T cell suppression or restrain their entry 
into tumors (10), down-regulation of MHC-I AgPP (11, 12) or antigen editing and loss (13). Various 
strategies have been used to enhance ICIT responsiveness, including induction of immunogenic cells 
death (ICD) by radiotherapy and chemotherapy (14). By enhancing the release of damage associated 
molecular patterns (DAMP) and other molecules, ICD stimulates tumor antigen uptake by antigen-
presenting cells (APC) that prime T cells against tumor antigens, as demonstrated by vaccination 
experiments (15). Primed T cells may accumulate in the tumor and lead to immune rejection as long as 
they can recognize and kill their targets (16). Such strategies are ineffective in cancers with low MHC-I or 
HLA-A/B/C expression (11, 16–19) . 
 PCa is a typical ICIT-refractory cancer, presumably due to low expression of HLA-A/B/C 
molecules that together with 2 macroglobulin form MHC-I heterodimers, which present tumor antigens to 
CD8+ CTL (20, 21). Using mouse models of PCa we found that the platin-based DNA-crosslinker 
oxaliplatin (Oxali) potentiates immune rejection of autochthonous or engrafted tumors after genetic or 
pharmacological depletion of PD-L1-expressing immunosuppressive IgA+ plasmocytes, which cause CTL 
exhaustion (22). Low dose Oxali also enhances mouse PCa regression in response to anti-PD-L1 
treatment (22). Similar results were obtained with low dose Oxali or photodynamic therapy in other cancer 
models (23, 24) but the underlying mechanisms have not been explored. As Oxali is known to induce ICD 
and T cell priming, we investigated whether its ability to potentiate the immune rejection of IgA+ 
plasmocyte- depleted or anti-PD-L1 treated low MHC-I prostate tumors also entails effects on the 
recognition and killing step of the cancer immunity cycle, which depends on CTL-MHC-I interactions (16, 
25). Here we show that Oxali and the structurally unrelated topoisomerase II inhibitor mitoxantrone (Mito) 
transcriptionally upregulate expression of MHC-I molecules and their cognate antigen presentation and 
processing machinery (AgPPM). This response, which takes place in human and mouse cancers, 
depends on activation of NF- B and nuclear translocation of the closely related histone (and lysine) acetyl 
transferases p300 and CREB binding protein (CBP). Whereas p300 ablation abrogated MHC-I AgPP 
induction and the synergy between low dose Oxali and PD-(L)1 blockade, it had no effect on induction of 
anti-tumor immunity by Oxali-killed PCa cells used as an immunogen.  
Results  
Oxaliplatin and mitoxantrone induce MHC-I AgPPM genes 
To determine the effect of Oxali and related drugs on gene expression in PCa cell lines used in our 
previous study (22), Myc-CaP cells were treated with different drugs at doses that induce no more than 
10 % cell death, and vital cells (SI Appendix, Fig. S1A and S1B) were analyzed by whole genome RNA 
sequencing (RNAseq) and ATAC-seq (Assay for Transposase-Accessible Chromatin) (26). Since CTL re-
invigoration by anti-PD-L1 induces IFN  production (27, 28), we also examined the effect of IFN alone or 
together with chemotherapy. Low-dose chemotherapy, in particular Oxali, induced marked changes in 
gene expression and chromatin accessibility depicted as Differentially Expressed Genes (DEG) and 
Differentially Accessible DNA Regions (DAR) (Fig. 1A and SI Appendix, Fig. S1C-S1F). The platinoid-
induced changes were usually augmented by IFN , although the effects of Oxali were broader than that of 
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IFN , which mainly enhanced gene expression magnitude rather than breadth. Some of the Oxali or IFN  
inducible gene sets were common to both agents (Fig. 1A). Pathway enrichment analysis (Fig. 1B) 
identified the most significantly enriched pathways, activated by Oxali (red, e.g. Epithelial-mesenchymal 
transition, TP53), IFN  (blue, e.g. Myc) or Oxali + IFN together (purple, e.g. IFN type I and II, AgPPM). 
Notably, while either Oxali or IFN  significantly enriched genes involved in MHC-I AgPP and IFN  
signaling, these effects were strongly enhanced when Oxali and IFN  were combined (Fig. 1B and SI 
Appendix, Fig. S2A-S2C). However, Oxali did not induce IFN  expression, indicating that its ability to 
induce MHC-I AgPPM components was not due to autocrine IFN  signaling. 
 Pathway enrichment analysis of DEGs that were responsive to Oxali plus IFN  revealed strong 
induction of genes related to type I and II IFN signaling and MHC-I AgPPM components, involved in 
protein folding, MHC-I complex assembly and peptide loading, as well as genes involved in the ER-
phagosome pathway and anti-viral responses (Fig. 1C and SI Appendix, Fig. S2D). Most of these genes 
were also induced by Oxali alone. To understand how these genes were induced we examined the 
ATAC-seq patterns of a gene cluster on mouse chromosome 17 harboring the Psmb9, Tap1, Psmb8, and 
Tap2 genes, coding for immunoproteasome components and peptide transporters (SI Appendix, Fig. 
S1E-S1F and S3A). Low dose Oxali, and to a lesser extent Cisplatin (Cispl), increased transcription factor 
(TF) accessibility at several sites within this locus (SI Appendix, Fig. S3A). Surprisingly, IFN  alone had 
little effect, if any, on chromatin structure (SI Appendix, Fig. S1F). Q-RT-PCR analysis further confirmed 
induction of AgPPM genes by Oxali and Cispl and to a lesser extent by Mito, alone or together with IFN  
(SI Appendix, Fig. S3B-S3D). A similar response pattern was displayed by the Nlrc5 gene coding for 
NLRC5/CITA, the master activator of the MHC-I AgPPM (Fig. 2A). ATAC-seq revealed increased Nlrc5 
chromatin accessibility after low dose Oxali or Cispl , but hardly any change after IFN  treatment (Fig. 
2B). Mito, Cispl and Oxali, but not IFN , induced Ifngr2 mRNA, but had little effect on chromatin 
accessibility of its gene (Fig. 2C-2D). Of note, the chromosome 17 region opened up by Oxali contains 
binding motifs recognized by BORIS and CTCF (SI Appendix, Fig. S3A), general TF responsible for 
chromatin opening (29). Low dose Oxali also increased 2 microglobulin ( 2M) and all tested 
chemotherapeutics induced surface and mRNA expression of H-2Kq, the predominant MHC-I molecule in 
Myc-CaP cells (Fig. 2E-2F and SI Appendix, Fig. S3D). Low-dose Oxali increased immunoproteasome 
activity measured with an LMP7/PSMB8-specific substrate, Ac-ANW-AMC, an effect that was potentiated 
by IFN  (Fig. 2G). 
Putative transcriptional regulators of MHC-I AgPPM induction 
We searched for signaling pathways and TF mediating MHC-I AgPPM and IFN R2 induction by low dose 
Oxali. RNA-seq and pathway enrichment analyses suggested involvement of IRF, STAT, NF- B, MYC 
family members and androgen receptor (AR) (Fig. 2H-2K, and SI Appendix, Fig. S3E-S3F). Whereas the 
IRF, STAT and NF- B pathways were upregulated by Oxali and potentiated by IFN , the MYC and to a 
lesser extent the AR pathway, both of which participate in PCa tumorigenesis (30–32), were 
downregulated after Oxali + IFN  treatment. Amongst IRF family members, IRF1, 7 and 9 were stimulated 
by Oxali and IFN , IRF2 was induced by Oxali and IRF8 mainly responded to IFN  (SI Appendix, Fig. 
S3F). Similarly, STAT1 and 2 were stimulated by Oxali, whereas IFN induced STAT1 and 3. JUN, ATF3, 
UBA7, CREB3, NFE2L1 and SOCS1 were induced by low-dose Oxali, along with NF- B1 (p105) and NF-
B2 (p100) (SI Appendix, Fig. S3F). ATAC-seq confirmed that Oxali, but not IFN  enhanced chromatin 
accessibility of the Nfkb1 locus (Fig. 2H). 
We employed two additional analytic approaches to identify master TF mediating treatment-
induced expression changes [LISA (33)] and TF binding enrichment within regions of differential 
chromatin accessibility [GIGGLE (34)]. These analyses predicted the master regulators (MRs) most likely 
to influence the DEGs (Fig. 2I) and DARs (Fig. 2J) by leveraging the complete set of TF binding datasets 
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available from the CistromeDB collection. The results further highlighted treatment-related directional TF 
associations (up/downregulated DEGs, open/closed DARs); Oxali: ESR1, NR3C1 and JUN; IFN : MYC, 
STAT1, ATF4 and FOS; Oxali + IFN : STAT1, YAP1, ESR1, IRF1, RELA and IRF8 (Fig. 2I-2J). DEG and 
DAR integration revealed 200 common TF, including IRFs and STATs (Fig. 2K). Notably, Oxali treatment 
elicited marked changes in histone methylation- and acetylation-related gene signatures (Fig. 2L) in 
agreement with the ATAC-seq data (SI Appendix, Fig. S1E-S1F). Subset analyses focusing on histone 
modifying factors implicated the involvement of the histone acetyltransferases (HATs) p300 and CBP and 
several histone deacetylases (HDACs) (SI Appendix, Fig. S4A).  
To confirm induction and/or activation of some of the above TF, PCa (Myc-CaP, TRAMP-
C2/TRC2) and colon cancer (MC38) cell lines were treated as above with or without IFN Protein 
immunoblotting (IB) and flow cytometric analyses confirmed induction of ER stress (P-eIF2  CHOP) and 
DNA damage (p-p53, H2AX, p-ATM) markers, IRFs (IRF1, p-IRF3, IRF7), STATs (P-STAT1 and 
STAT1), CREB1, JUNB, type I IFN inducing proteins (cGAS, STING), PSMB9, and NF- B signaling 
components (I B , RELA/p65, P-p65) (SI Appendix, Fig. S4B-S4G). 
Chemotherapy stimulates HAT nuclear localization and activity 
Chromatin structure opening, as revealed by ATAC-seq analysis, depends on histone acetylation (35). 
Importantly, Oxali treatment of Myc-CaP cells, increased HAT enzymatic activity within 3 h and its effect 
was comparable to that of an HDAC inhibitor (HDACi) (Fig. 3A-3B). Oxali and Mito also increased total 
p300, acetylated CBP/p300 and K310-acetylated RELA/p65 nuclear amounts (Fig. 3C). IFN  also 
increased nuclear p300, but its effect was considerably weaker than that of Oxali (Fig. 3C-3D). Both Oxali 
and HDACi induced p300 nuclear translocation in murine PCa cells (Fig. 3D) and human PCa organoids 
(SI Appendix, Fig. S5A). ChIP experiments showed that Oxali induced p300 and RELA/p65 recruitment to 
the Nlrc5 and Ifngr2 promoters and p300 recruitment to the Tap1, Psmb8/9 promoters (Fig. 3E-3F). 
These promoter regions also exhibited increased H3K14 and K27 acetylation after Oxali treatment (Fig. 
3G). Oxali-induced H3K14 acetylation at nuclear foci, similar to those revealed by p300 antibody staining, 
was also observed by IF analysis (SI Appendix, Fig. S5B). Increased RELA/p65 K310 acetylation, which 
was attenuated after treatment by p300/CBP inhibitors, was confirmed by IB and IF analyses (SI 
Appendix, Fig. S5C-S5D). Using HA- or Myc-tagged p300 and Flag-tagged Stat1 expression vectors 
followed by immunoprecipitation (IP), we confirmed binding of p300 to endogenous RELA/p65 and 
transfected STAT1 (SI Appendix, Fig. S5E), an interaction that stimulates p300 acetyltransferase activity 
(36). To investigate the basis for p300 nuclear translocation, we examined induction of HLA-B–associated 
transcript 3 gene product, BAT3, which controls intracellular p300 distribution (37). IF analysis confirmed 
Oxali-induced nuclear translocation of both p300 and BAT3 (SI Appendix, Fig. S5F).  
p300 and CBP control MHC-I AgPPM expression and neoantigen amounts  
We generated cell lines deficient in p300 or CBP (Fig. 4A and SI Appendix, Fig. S6B). p300 -Myc-CaP 
cells expressed CBP and upregulated its expression upon Oxali treatment, and CBP -Myc-CaP cells 
behaved similarly. Notably, p300 -Myc-CaP cell viability did not differ from that of parental cells and 
neither p300 nor CBP ablation reduced total or Oxali-induced total RELA/p65 protein or Nfkbia mRNA 
(Fig. 4A and SI Appendix, Fig. S6A-S6C). However, Tap1, Psmb9, Nlrc5, Infgr2 and Ifna mRNA 
inductions were attenuated by both p300 or CBP ablations, whereas Irf1 and Erap1 mRNA inductions 
were only reduced in p300 -Myc-CaP cells (Fig. 4B-4F and SI Appendix, Fig. S6D-S6E). Both the p300 
and CBP deficiencies attenuated induction of Sec22b mRNA (Fig. 4G), coding for a vesicle-trafficking 
protein that regulates phagosomal maturation and antigen crosspresentation (38). Consequently, both 
deficiencies hampered Oxali- and Mito-induced H-2Kq mRNA and surface expression (Fig. 4H and SI 
Appendix, Fig. S6F-S6G). A p300/CBP inhibitor also attenuated H-2Kq protein, and Psmb9 and Tap1 
mRNA inductions (SI Appendix, Fig. S6H-S5I). Conversely, treatment of Myc-CaP cells with non-lethal 
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doses of the HDACi panobinostat (LBH589) induced Nlrc5, Psmb9, and Tap1 mRNAs and surface H-2Kq 
(SI Appendix, Fig. S6J-S6L).  
To gather information about p300 and CBP in human cancer, we examined the TCGA data set 
and found significant correlations between EP300 or CBP mRNAs and genes identified by our integrative 
RNA-seq and ATAC-seq analyses, including RELA, STAT1, NFKB1, IFNGR2 and NLRC5 (Fig. 5A-5B, 
and SI Appendix, Fig. S7A). Similar correlations were found between histone modifiers and genes 
involved in MHC-I AgPP and T cell inflammation, particularly in human liver cancer (SI Appendix, Fig. 
S7B-S7C). Cancers with EP300/CBP loss-of-function [LOF; deletion and/or copy number variants (CNV) 
loss] showed lower ERAP1 and IFNGR1 or HLA-A expression (Fig. 5B). Curiously, EP300 and CBP were 
described both as oncogenes and oncosuppressors (39, 40). Phenotypes associated with heterozygous 
alterations were described in B cell lymphoma and Rubinstein-Taybi syndrome-1 (41, 42), suggesting 
dosage-dependent EP300/CBP function. We found that multiple CNVs, both gains and losses, affected 
EP300 and CBP in HCC (LIHC) and PCa (PRAD) (Fig. 5A, and SI Appendix, Table S1) and correlated 
with their expression (SI Appendix, Fig. S7D). Interestingly, increased EP300 and CBP copy numbers 
correlated with improved LIHC patient survival (Fig. 5C). We also analyzed CNVs of genes involved in 
MHC-I AgPPM and IFN  signaling (Fig. 5D-5E, SI Appendix, Fig. S8A and Table S1). We found that LIHC 
and PRAD patients with gains in MHC-I AgPPM genes showed more frequent EP300/CBP LOF (Fig. 5D-
5E, SI Appendix, Table S1), suggesting a compensatory mechanism that allows cancers with elevated 
MHC-I AgPPM evade immune-recognition. We also analyzed the number and the fraction of neoantigens 
in different cancers (SI Appendix, Fig. S8B-S8C). Remarkably, cancers with EP300/CBP LOF showed 
higher neoantigen amount (Fig. 5F and SI Appendix, Fig. S8D), supporting the notion that tumor 
immunoediting shapes the neoantigen landscape (43, 44) and that EP300/CBP may be part of this 
process.  
NF- B signaling and MHC-I AgPPM induction  
Electron microscopy (EM) suggested that Oxali-treated cells underwent nucleolar/ribosomal and 
mitochondrial stress indicated by the condensed appearance of both organelles (Fig. 6A-6B, and SI 
Appendix, Fig. S9A). However, the absence of nuclear or mitochondrial fragmentation confirmed that 
most of the stressed cells remained viable. Oxali-induced nucleolar/ribosomal stress (45, 46), which was 
confirmed by Mass Spectrometry (MS) and RNA-seq analyses (SI Appendix, Fig. S9B-S9E), can account 
for NF- B activation (47). To determine NF- B’s role in the response to Oxali, we generated RELA/p65-
deficient cell lines (SI Appendix, Fig. S10A-S10B). Consistent with the ChIP experiments shown above 
(Fig. 3E), RELA/p65 was needed for full induction of Ifngr2, Tap1, Psmab9, Nlrc5 and Bat3 mRNAs by 
low dose Oxali (Fig. 6C-6E, and SI Appendix, Fig. S10C-S10D). RELA/p65 ablation strongly inhibited 
surface H-2Kq induction by Oxali but barely affected the response to IFN  (Fig. 6F). BAT3 and p300 
nuclear translocation was also attenuated in RELA-deficient cells (Fig. 6G, and SI Appendix, Fig. S10E). 
Treatment of Myc-CaP cells with IKK  inhibitors also reduced H-2Kq surface expression (SI Appendix, 
Fig. S10F). We also generated IRF1, STING/cGAS, STAT1, IFN R2 and VDAC1 deficient Myc-CaP cells 
(Fig. 6H and SI Appendix, Fig. S11A-S11E). VDAC1 (voltage dependent anion channel 1) was recently 
shown to be required for the cytoplasmic release of mitochondrial (mt) DNA (48), which is considerably 
elevated in Oxali-stressed cells (SI Appendix, Fig. S11E-S11F). Notably, VDAC-1 ablation strongly 
reduced Rela, p300 and Irf-1 mRNA induction by Oxali (SI Appendix, Fig. S11G). Ablation of VDAC1 and 
IRF1, but not STAT1 or IFN R2 abrogated Oxali-induced expression of surface H-2Kq and MHC-I AgPPM 
genes (Fig. 6H, and SI Appendix, Fig. S11H-S11K). Ablation of cGAS led to a small decrease in H-2Kq 
expression and no effect on induction of most AgPPM genes (Fig. 6H, and SI Appendix, Fig. S11H-
S11K). Not surprisingly, STAT1, IRF-1 and IFN R2 as well as VDAC1 and cGAS were required for H-2Kq 
surface expression in Myc-CaP cells treated with IFN  alone or IFN  + Oxali (SI Appendix, Fig. S11L). 
Oxali treatment also led to modest induction of PD-L1, a response that was enhanced by exogenous IFN  
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and was IRF1-dependent (SI Appendix, Fig. S11M), which has previously been shown to contribute to 
efficacy of ICIT (49). PD-L1 induction was not affected by TAP1 ablation, which completely prevented H-
2Kq surface expression. 
Chemotherapy induced functional antigen presentation 
To confirm that Oxali stimulates neoantigen presentation we used MS to determine the  peptidomes of H-
2Kb and H-2Db molecules isolated from MC-38 cells after treatments, as described previously (50). 
Treatment with IFN + Oxali induced higher amounts (based on area under the curve) of H-2Kb-bound 
peptides relative to Oxali or IFN  alone (SI Appendix, Fig. S12A). Although IFN  led to higher amounts of 
H-2Db-bound peptides than Oxali in this particular cell line, chosen for its high MHC-I expression, some 
peptides were more efficiently presented after IFN + Oxali treatment. 
The T cell activating ability of the Oxali-induced MHC-I bound peptides was confirmed using 
TRC2 PCa cells expressing high-, medium-, and low-affinity ovalbumin (Ova) variants. Oxali treatment 
stimulated H-2Kb presentation of the SIINFEKL epitope, especially in TRC2-N4 cells made to express the 
high-affinity (WT) variant (SI Appendix, Fig. S12B). When incubated with OT-I CD8+ T cells, whose T-cell 
receptor (TCR) is SIINFEKL-specific, Oxali treated TRC2-N4 cells were more readily killed by activated 
OT-I T cells (SI Appendix, Fig. S12C-S12D). OT-I T cells enhanced presentation of the WT SIINFEKL 
epitope by TRC2-N4 cells in the absence of Oxali but had no effect on cells expressing the medium 
(TRC2-G4)- or low (TRC2-E1)-affinity variants. These results are consistent with a previous publication 
showing that only the high-affinity SIINFEKL epitope induces IFN  secretion by OT-I cells (51), and further 
establish that the effect of Oxali is mechanistically distinct from that of IFN  and dependent on neoantigen 
affinity and TCR activation. 
We examined mouse and human cancer cell lines that differ in basal MHC-I expression. As 
described above, cells with high basal MHC-I such as MC-38 and B16 melanoma showed a weak 
response to platinoids alone but that response, including Nlrc5 mRNA and surface MHC-I, was 
augmented by IFN  (SI Appendix, Fig. S13A-S13B). In other cancer cells, e.g. the mouse melanoma 
YUMM cell lines, we observed a considerable variation in the response (SI Appendix, Fig. S13C). Strong 
Oxali-induced MHC-I surface expression was detected in human PC3 PCa cell line, PCSD1 cells, a 3D 
organoid culture from a Patient-Derived Xenograft (PDX) of bone metastatic PCa, certain primary 
melanoma cells and MIA PaCa-2 cells, representing ICIT-refractory PDAC (SI Appendix, Fig. S13D-
S13G).  
Activation of p300/CBP and NF- B is needed for Oxali + anti-PD-L1 synergy 
We sorted tumor-infiltrating CD8+ T cells (TI-CD8+) from subcutaneous (s.c.) Myc-CaP tumors, 
treated with either Oxali, anti-PD-L1, Oxali + anti-PD-L1 (combo) or left untreated (Ctrl) and performed 
scRNA-seq (Fig. 7A, SI Appendix, Fig. S14A). Several clusters of TI-CD8+ cells with distinguishable gene 
expression and cluster specific pathway enrichment patterns were detected (Fig. 7B, and SI Appendix, 
Fig. S14B-S14H). Notably, elevated Gzmb, Gzam, Prf1, Tbx21(Tbet) mRNAs were detected in TI-CD8+ 
from combo-treated mice (SI Appendix, Fig. S14E). Only combo therapy was associated with a 
significantly higher Teff signature (Fig. 7C and SI Appendix, Fig. S14F-S14H).  
Next, we examined the involvement p300, CBP, IFN R2 and NF- B/RelA in Oxali-enhanced and 
CTL-mediated rejection of Myc-CaP tumors (Fig. 7A). The synergistic inhibition of tumor growth by Oxali 
+ anti-PD-L1 was completely abrogated by p300 and CBP ablation in Myc-CaP cells (Fig. 7D-7G, and SI 
Appendix, Fig. S15A). IFN R2 ablation also abolished the response to Oxali + anti-PD-L1 (Fig. 7G-7H 
and SI Appendix, Fig. S15B). As found in vitro, low-dose Oxali induced expression of Ifngr2, Tap1, 
Psmb9, and Nlrc5 mRNA in Myc-CaP tumors (Fig. 7I-7K and SI Appendix, Fig. S15C). PD-L1 blockade 
did not affect Ifngr2 mRNA expression, although it potentiated Tap1, Psmb9, and Nlrc5 mRNA induction 
by Oxali, probably through IFN  secretion by reinvigorated CTLs (Fig. 7I-7K and SI Appendix, Fig. S15C). 
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Indeed, IFN R2 ablation had little effect on the response to Oxali alone while abrogating the response to 
Oxali + anti-PD-L1. Tap1, Psmb9, and Nlrc5 induction by Oxali or Oxali + anti-PD-L1 was abrogated after 
p300 ablation (Fig. 7I-7K). IFN R2 and p300 ablation also attenuated therapy-induced MHC-I (H-2Kq and 
H-2Dd) surface expression on CD45- cancer cells (Fig. 7L, and SI Appendix, Fig. S15D-S15E), but had 
no effect on PD-L1 expression (SI Appendix, Fig. S15F). IFN R2 and p300 ablations also had no effect 
on H-2Kq expression by tumor-infiltrating CD11c+ dendritic cells (SI Appendix, Fig. S15G). In accordance 
with scRNA-seq data, the Oxali+anti-PD-L1 combo increased the percentage and/or total numbers of 
tumor-infiltrating CD8+ and CD4+ T cells, CD107+IFN  CTLs, IFN  CD8+ and TNF+IFN  CD8+ T cells, 
CD8+CD44+ Teff cells and CD8+CD44+PD1+TIM-3+ T cells analyzed by flow cytometry (Fig. 7M-7N and SI 
Appendix, Fig. S16A, S16C-S16H). Similar results were obtained for splenic CD8+ T cells (SI Appendix, 
Fig. S16B, and S16I-S16K). Of note, p300 or IFN R2 ablation had little effect on tumor infiltrating effector 
CD8+ T cells, whose numbers were similarly increased after Oxali + anti-PD-L1 treatment in p300- or 
IFN R2-expressing and non-expressing tumors (Fig. 7M-7N, and SI Appendix, Fig. S16C-S16H). By 
contrast, the Oxali + anti-PD-L1 combo decreased the fractions of each tumor occupied by CD45- 
“cancer” cells, an effect that was most pronounced in WT tumors relative to p300 or IFN R2 ablated 
tumors (Fig. 7O). NF- B/RelA ablation also abolished the response to Oxali + anti-PD-L1 (Fig. 8A), 
consistent with its requirement for MHC-I and IFN R2 induction (Fig. 8B, and SI Appendix, Fig. S17A), 
Thus, Oxali-induced upregulation of MHC-I AgPPM genes in malignant cells is important for the final 
recognition and killing stage of the cancer-immunity cycle (25) but has no role in ICIT-induced CTL 
reinvigoration.  
Of note, ICD-mediated T cell priming proceeded normally in the absence of p300. FVB mice were 
immunized with Oxali-killed p300-proficient or -deficient Myc-CaP cells and challenged one week later 
with vital p300-proficient or -deficient Myc-CaP cells (Fig. 8C and SI Appendix, Fig. S17B). Myc-CaP cells 
grew significantly slower in FVB mice immunized with either p300-proficient or -deficient Myc-CaP cells 
compared to non-vaccinated mice, indicating that p300 has no effect on ICD-mediated T cell priming.  
Discussion  
 ICIT-induced tumor rejection depends on activation of the cancer-immunity cycle, initiated by 
priming of tumor-directed T cells and terminated by killing of the targeted cancer cells by effector CTLs 
(16, 25). T cell priming can be enhanced by certain chemotherapeutic drugs capable of inducing ICD (14) 
and ICIT (4, 27). Nonetheless, even highly effective T cell priming and ICIT do not ensure successful 
CTL-mediated tumor killing, which requires MHC-I mediated presentation of tumor specific antigens (2, 
14, 17, 52). Many cancers, especially PCa (SI Appendix, Fig. S7E) (53), evade immune elimination by 
downregulating MHC-I molecules or essential AgPPM components (11). Here we show that two different 
chemotherapeutic drugs, oxaliplatin (Oxali) and mitoxantrone (Mito) used at rather low concentrations, 
enhance CTL-mediated cancer cell recognition and killing through transcriptional induction of MHC-I 
AgPP (Schematic summary, SI Appendix, Fig. S17C). Although induction of MHC-I antigen presentation 
by chemotherapy and radiotherapy was described (54–56), the underlying mechanisms were only partly 
explored and attributed to type I IFN signaling. However, recent reports showing that sustained type I IFN 
signaling contributes to anti-PD-(L)1 resistance (57, 58) cast doubt on the role played by type I IFN in 
chemotherapy or radiotherapy induced immune stimulation. Our results show that Oxali renders low 
MHC-I expressing PCa cells responsive to anti-PD-1 therapy through transcriptional activation of the 
MHC-I AgPPM by NF- B and p300/CBP, but not via the IFN-responsive TF STAT1. Ablation of p300 (or 
CBP) or NF- B/RelA abolished the ability of low dose Oxali to synergize with anti-PD-L1 and induce 
rejection of Myc-CaP tumors. Consistent with their direct involvement in transcriptional activation of MHC-
I AgPPM genes, ablation of p300 or RelA abrogated Tap1, Psmb9 and Nlrc5 induction in Myc-CaP 
tumors, but had no effect on tumor infiltration by effector CD8+ cells. Tumor infiltrating CTLs, however, 
were strongly increased after anti-PD-L1 + Oxali treatment as indicated by scRNA-seq and flow 
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cytometry. In contrast, ablation of p300 had no effect on the ability of Oxali-killed Myc-CaP cells to prime 
anti-tumor immunity, as indicated by vaccination experiments. 
Oxali treatment triggers nucleolar/ribosomal stress (45, 46), possibly through its preferential 
interaction with rDNA or inhibition of rRNA synthesis, which represents almost half of the human genome 
(59). By virtue of its highly repetitive nature, rRNA integrity and expression are also sensitive to loss of 
topoisomerase II activity (60), a sequelae of Mito treatment. EM analysis of Oxali treated Myc-CaP cells 
confirmed altered nucleolar morphology, consistent with nucleolar stress, which can trigger NF- B 
activation (47). By inducing Bat3 transcription, RelA/NF- B supports p300/CBP nuclear translocation, 
further increasing its own activity and stimulating histone acetylation. Oxali treatment can also enhance 
NF- B activity via mitochondrial stress, whose presence in Myc-CaP cells is suggested by increased 
mitochondrial density and appearance of fragmented mtDNA in the cytosol. Ablation of VDAC1, through 
which mtDNA exits the mitochondrion (48), reduced p300 and Rela mRNA expression and abrogated 
induction of NLRC5 and different MHC-I AgPPM components. NF- B is also needed for induction of 
IFN R2. Although IFN R2 ablation had no effect on Oxali-induced MHC-I surface expression in cultured 
cells, it abrogated the rejection of Myc-CaP tumors and inhibited induction of MHC-I AgPPM genes in 
mice treated with anti-PD-L1 + Oxali. We postulate that IFN R2 induction in Myc-CaP cells makes them 
more responsive to IFN  secreted by tumor infiltrating CTL.  
Neither Oxali nor Mito were developed as immunostimulatory drugs. It is therefore 
understandable that their immunogenic activity depends on multiple signaling pathways that are activated 
on induction of sub-lethal DNA damage and nucleolar and mitochondrial stress. Given the number of 
different signaling pathways activated by Oxali or Mito, it is rather surprising that ablation of either 
p300/CBP or RelA results in almost complete inhibition of the drug-induced immunogenic response. 
These findings parallel the cardinal importance of p300/CBP and NF- B in activation of the MHC-I AgPP 
system. p300 plays a key role in assembly of the NLRC5 transcriptional activation complex and  NF- B 
recruitment to MHC-I genes (61). Notably, downregulation of NLRC5 has been observed in multiple 
cancer types, resulting in evasion of immune elimination (12). Conversely, we found that cancers with 
NLRC5 gain were more likely to undergo CPB/EP300 loss. We also found that EP300 and CBP LOF 
mutations and CNVs are rather common in certain types of cancer, and that their presence correlates 
with reduced MHC-I AgPPM expression. These genetic alterations seem more common than HLA loss 
mutations. Moreover, HCC and PCa with gain of HLA, PSMB and TAP genes, possibly due to 
chromosome 6p amplification (62), show higher frequency of CBP/EP300 loss, which may allow them to 
undergo immune evasion. Based on its loss in several types of cancer, EP300 was suggested to behave 
as a tumor suppressor gene (63, 64). We suggest that CBP/EP300 loss promotes tumor growth by 
enabling immune evasion. One way to restore recognition of tumors with monoallelic EP300/CBP loss is 
treatment with low-dose Oxali or Mito or more potent and specific EP300/CBP activators.  
 
Material and Methods  
Detailed information about the animal models, in-vivo and in-vitro studies, flow cytometry, qRT-PCR, 
Immunoblot analysis, bioinformatic analysis, statistics and materials is provided in SI Appendix Material 
and Methods and Table S2.  
Data and Materials Availability 
This study did not generate new unique materials. The Sequencing data are available in NCBI’s Gene 
Expression Omnibus database. Mouse ATAC-seq (GSE126287) and RNA-seq (GSE126274). Single cell 
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Fig. 1. Chemotherapy induces MHC-I AgPPM genes. (A) Heatmap showing all DEGs identified 
in bulk RNAseq of Myc-CaP cells treated with IFNγ (0.2 or 2 ng/mL), Oxali (2 μM), or both 
(Combo) (left). Venn diagram shows overlapping DEGs between IFNγ (2 ng/mL), Oxali and 
Combo treatment groups relative to Ctrl (middle) and Heatmap shows all DARs identified in bulk 
ATAC-seq of Myc-CaP cells treated as indicated relative to control (right). (B) GSEA was 
applied to expression profiles specific to each treatment group relative to Ctrl. Top 30 
significantly enriched pathways for each respective comparison are shown. Some pathways 
were considered both IFNγ and Oxali driven (purple), while others were specific to either IFNγ 
(blue) or Oxali (red). (C) Functional enrichment was applied to genes classified with additive 
response to combination therapy. The top 20 enriched REACTOME pathways are shown.  
Fig. 2. Transcriptional regulators of Oxali-induced MHC-I AgPPM genes. (A) RNAs from Myc-
CaP cells incubated as indicated with IFNγ, Mito, Oxali, Carbo, or Cispl for 48 h were analyzed 
by qRT-PCR using Nlrc5 primers. (B-C) Candidate genomic loci for Nlrc5 (B) and Ifngr2 (C), 
showing library-size normalized read pair pileup profiles determined by ATAC-seq across 
samples. Expression of respective genes determined by RNA-seq is also shown. (D) RNAs from 
Myc-CaP cells incubated as indicated were analyzed by qRT-PCR using Ifngr2 primers. (E) 
Myc-CaP cells incubated with Oxali for 12 h were stained with β2M antibody (green) and 
phalloidin (red) and counterstained with DAPI. Magnification bar: 20 μm. (F) Myc-CaP cells 
treated as indicated were analyzed for surface MHC-I (H-2Kq) expression by flow cytometry. 
One-way ANOVA analysis (***) and multiple comparison confirmed the results. (G) Myc-CaP 
cells were incubated as indicated and lysed. LMP7 (PSMB8) immunoproteasome activity was 
measured using a fluorogenic LMP7-specific substrate peptide Ac-ANW-AMC. (H) Candidate 
genomic locus for Nfkb1 showing read density profiles determined by ATAC-seq across 
samples. (I) Transcriptional regulator inference analysis (LISA) was applied to DEGs identified 
in comparisons of IFNγ (2 ng/mL), Oxali (2 M), and both (Combo) treated cells relative to 
control, as well as to genes classified with additive response (top 500 upregulated, 
downregulated DEGs). The top 20 enriched regulators of upregulated (red) and downregulated 
(blue) DEGs are noted. (J) Transcriptional regulator binding sites enrichment analysis (GIGGLE) 
was applied to DARs identified in comparisons of IFNγ, Oxali, and Combo treated cells relative 
to control, as well as to regions classified with additive response. The top 20 enriched regulators 
of opened (red) and closed (blue) DARs are noted. (K) 200 common genes were identified by 
comparing TF found by DEGs and DARs analysis. (L) GSEA was applied to expression profiles 
determined in Oxali treated cells relative to control. The literature-curated known regulatory 
elements from ORegAnno database are shown. Candidate enrichment plots for representative 
pathways related to histone methylation (top) and acetylation (bottom) are shown. Two-sided t-
test (means ± s.e.m), and Mann–Whitney test (median) were used to determine significance 
between two-groups. One-way ANOVA analysis and multiple comparison confirmed the 
results.*P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. Specific n values are shown in (A, 
D, F, G), each experiment includes at least three biological replicates. 
Fig. 3. Oxaliplatin and mitoxantrone stimulate HAT activity and nuclear localization. (A-B) Myc-
CaP cells incubated with Oxali (2 or 4 M) or the HDACi panobinostat (LBH589; 20 nM) for the 
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indicated times were lysed and analyzed for HAT activity using H3 as a substrate. (C) Nuclear 
extracts of Myc-CaP cells treated with Oxali, Mito and/or IFNγ were IB analyzed for p300, 
acetylated-CBP/p300, acetylated-RELA/p65 (lysine K310) and lamin B1 (loading control). (D) 
Myc-CaP cells treated as indicated for 12 h were stained with anti p300 (green) and phalloidin 
(red; actin cables). Nuclei were counter stained with DAPI (blue). Magnification bar: 20 m. (E-
G) Untreated and Oxali treated Myc-CaP cells were subjected to ChIP analysis with control IgG 
and antibodies to p65/RelA, p300 as indicated (E-F) or acetylated H3 (lysine K9, K14, and K27) 
(G). Precipitation of the indicated promoter regions was determined by PCR. Two-sided t-test 
(means ± s.e.m), and Mann–Whitney test (median) were used to determine significance. 
*P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. Specific n values are shown in (A, E), 
each experiment includes at least three biological replicates. 
Fig. 4. p300 and CBP control Oxali-induced MHC-I AgPPM genes. (A) Parental (shRNA-Ctrl) 
and p300 or CBP silenced Myc-CaP cells were incubated with Oxali for 48 h. Nuclear extracts 
were IB analyzed for p300, CBP, p65/RELA and HDAC1 (loading control). (B-G) RNA 
expression in above cells was analyzed by qRT-PCR with the indicated primers. (H) Parental 
and gene edited Myc-CaP cells were incubated with Oxali and analyzed for surface MHC-I (H-
2Kq) expression by flow cytometry. Two-sided t-test (means ± s.e.m), and Mann–Whitney test 
(median) were used to determine significance unless indicated otherwise. *P < 0.05; **P < 0.01; 
***P < 0.001; NS, not significant. Specific n values are shown in (B-H). Each experiment 
includes at least three biological replicates. 
Fig. 5. p300/CBP control MHC-I AgPPM expression in human cancers. (A) EP300 and CBP 
CNV losses and gains in LIHC (n = 369) and PRAD (n = 492). Key: dark blue (homozygous 
deletion), light blue (one copy loss), white (no CNV), pink (one copy gain), and red (high 
amplification). (B) Comparison of immune gene expression between LIHC EP300/CBP LOF and 
non-LOF groups. Non-viral patients are included for comparison of CBP, EP300, ERAP1, and 
IFNGR1 expression. HLA-A expression was compared between EP300/CBP LOF and non-LOF 
HBV-infected groups. (C) Kaplan-Meier survival curves of LIHC patients with single gain (n = 
34), no CNV (n = 165), and single loss (n = 92) events in EP300/CBP. P-values are based on 
log rank test. (D-E) Enrichment comparison of LIHC (D) and PRAD (E) with or without 
EP300/CBP LOF or no CNV versus CNV gain in the indicated gene groups: MHC-I AgPPM 
(HLA/PSMBs/TAPs), STAT1/IFNGR1/IFNGR2, β2M and NLRC5. Fisher’s exact test was used 
to determine significance. (F) Landscape of high affinity neoantigens in four tumor types: PRAD 
(n = 492), LIHC (n = 356), LUSC (n = 473), and SKCM (n = 445). Groups were separated into 
EP300/CBP LOF (green dots) and non-LOF for neoantigen analysis. Mutations receiving a rank 
score < 2 and < 0.5 were considered binding and strong binding, respectively. P-values are 
based on Wilcoxon rank-sum test. Expression of neoantigens was determined from TCGA 
mRNA-seq reads. Two-sided t-test (means ± s.e.m), and Mann–Whitney test (median) were 
used to determine significance unless indicated otherwise. One-way ANOVA analysis and 
multiple comparison confirmed the results. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not 
significant. Specific n values are shown in (A-F). Each experiment includes at least three 
biological replicates. 
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Fig. 6. Role of NF-κB signaling in Oxali-induced MHC-I AgPPM expression. (A, B) Myc-CaP 
cells treated as indicated were fixed and examined by electron microscopy. Magnification bars 
are indicated in each image. White arrows indicate nucleolar stress. 10 representative images 
from each treatment group were analyzed and mitochondria/cytoplasm ratios were determined 
(B, right). (C-E) Parental (shRNA-Ctrl) or Rela/p65-silenced Myc-CaP cells were incubated with 
Oxali as indicated. RNAs were analyzed by qRT-PCR with the indicated primers. The results 
were confirmed using three different Rela/p65 shRNAs. (F) Myc-CaP cells described in (C) were 
treated as indicated and analyzed for surface MHC-I (H-2Kq) expression. (G) Parental or 
Rela/p65-silenced Myc-CaP cells were treated as indicated and stained with mouse-anti p300 
(green) and rabbit-anti BAT3 (red). Nuclei were counterstained with DAPI (blue) (n = 3). 
Magnification bar: 20 m. (J) Parental and gene edited (Ctrl, CRISPR/Cas9) or shRNA silenced 
Myc-CaP cells were treated as indicated and analyzed for surface MHC-I (H-2Kq) expression. 
(B-F, H) Two-sided t-test (means ± s.e.m), and Mann–Whitney test (median) were used to 
determine significance. One-way ANOVA and multiple comparisons were used to confirm 
significance. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. Specific n values are shown 
in (B-F). Each experiment includes at least three biological replicates. 
Fig. 7. Oxali + anti-PD-L1 synergy depends on p300/CBP and IFNγR2 expression. (A) 
Schematic description of in vivo experiments. Mice bearing s.c. Myc-CaP tumors were allocated 
into 4 treatment groups: (1) Control, (2) Oxali (6 mg/kg; weekly), (3) anti-PD-L1 (10 mg/kg; 
weekly), and (4) Oxali + anti-PD-L1 (weekly). After 4 treatment cycles, during which tumor size 
was measured,the mice were euthanized and analyzed. (B) UMAP representation of total T cell 
populations profiled by scRNAseq. Eleven distinct clusters were identified (Figure S14B-S14C). 
Proportional contributions of each cluster to sample-specific T cell populations is shown. Total 
cell numbers in each cluster are noted in Figure S14D. (C) Enrichment plots for candidate 
pathways defining CD8+ Teff over Tmem and Tnaïve cells. Enrichment plots for the comparison 
between control and combo treatment is shown (other comparisons are shown in S14H). (D-F, 
H) Mice bearing s.c. Myc-CaP tumors generated by control (D), p300-silenced (E-F), and Ifngr2 
ablated (Clone 1) (H) cells were treated as described in (A). Specific n values are shown in each 
panel. Transient Cas9 expression and stable shRNA transfectants were used to avoid immune 
responses. Each dot is a treatment group, mean ± s.e.m. (G) Tumor weights for the indicated 
experimental groups (n = 3-8). (D-H) Two-sided t-test (means ± s.e.m) and two-way ANOVA 
were used to determine significance. (I-K) Total tumor RNA was analyzed by qRT-PCR for 
expression of the indicated genes. (L-N) Single cell tumor suspensions were analyzed for H-2Kq 
(L) expression on CD45- cells, total number of TI-CD8+ (M) and effector CD8+IFNγ+CD107+ T 
cell subsets (N). (O) Solid tumor composition (% cancer cells) was determined by gating on 
CD45- cells. (G, I-O) Each dot represents a mouse. Mann–Whitney test (median) was used to 
determine significance. One-way ANOVA and multiple comparisons were used to confirm 
significance. Specific n values are shown in D-O. 
Fig. 8. Oxali-enhanced immune rejection requires NF-κB signaling. (A) Mice bearing s.c. Myc-
CaP tumors generated by control and RelA-silenced cells were treated and analyzed as 
described in Figure 7A. Each dot represents a treatment group mean ± s.e.m. (B) Single tumor 
cell suspensions were analyzed for H-2Kq (left) and H-2Dd (right) expression on CD45- cells. 
(C) Scheme of vaccination experiments (left). Two groups of mice were immunized with lysates 
of Oxali-killed shRNA-ctrl (MCwt) or p300-silenced (MC-p300Δ) Myc-CaP cells. After 7 days, 
mice were s.c. inoculated with live shRNA-ctrl (MCwt) cells. Live shRNA-ctrl (MCwt) cells were 
also implanted into non-immunized mice as a control. Tumor growth curves are shown (right). 
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(A-C) Two-sided t-test (means ± s.e.m) and two-way ANOVA were used to determine 
significance. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. Specific n values are shown 
in (A-C). 








